Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H9A5
UPID:
CNO10_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H9A5; B7Z7L1; F8WAF2; Q9BU30; Q9H5J7; Q9H8X1; Q9H9W0; Q9HAH3; Q9UFJ2
Background:
CCR4-NOT transcription complex subunit 10 plays a pivotal role in mRNA deadenylation, a process crucial for mRNA degradation and regulation. As a component of the CCR4-NOT complex, it influences various cellular processes including miRNA-mediated repression and translational repression, underscoring its importance in gene expression regulation.
Therapeutic significance:
Understanding the role of CCR4-NOT transcription complex subunit 10 could open doors to potential therapeutic strategies.